Hormonal IUD (Mirena/Kyleena) in Girls Under 12: Transitioning to Adult Care

Why Would a Girl Under 12 Have a Hormonal IUD?

A levonorgestrel IUD placed before a girl reaches her twelfth birthday is almost never about contraception. The indication is medical. Three situations account for the majority of pediatric placements.

Bleeding disorders and heavy menstrual bleeding. Von Willebrand disease affects roughly 1 in 100 women and girls, and in those with severe phenotypes, the onset of menarche can produce hemorrhage requiring transfusion. A 2020 case series published in the Journal of Pediatric and Adolescent Gynecology documented LNG-IUD placement in girls as young as nine for menorrhagia secondary to platelet dysfunction, with significant reduction in bleeding scores after six months.

Endometriosis diagnosed in childhood. Endometriosis is documented in girls before age 12, particularly in those with outflow tract anomalies. ACOG Practice Bulletin 114 acknowledges LNG-IUD use as a second-line hormonal option for endometriosis-associated pain when combined oral contraceptives fail or are not tolerated, and this guidance applies across reproductive-age patients including adolescents.

Oncologic and surgical endometrial suppression. Girls receiving pelvic radiation or certain chemotherapy regimens may be offered endometrial protection. In this context, the IUD's primary action, local progestin delivery with minimal systemic absorption, is especially appealing when systemic hormones carry additional risk.

What the Device Actually Does in a Prepubertal Uterus

The prepubertal uterus is smaller than the adult uterus. Standard Mirena (52 mg, 32 mm frame) may not fit without a modified insertion technique or anesthesia. Kyleena (19.5 mg, 28 mm frame) has a slightly narrower profile and is sometimes preferred in nulliparous or prepubertal patients, though neither device carries an FDA indication specifically for this age group.

Levonorgestrel from the IUD acts locally by thickening cervical mucus, suppressing endometrial proliferation, and reducing prostaglandin production. Systemic absorption is low: serum LNG in Mirena users averages 150 to 200 pg/mL, compared to 1,500 to 2,000 pg/mL in combined oral contraceptive users. This pharmacokinetic advantage matters in young patients because it minimizes interference with the hypothalamic-pituitary-gonadal axis during pubertal development.

The Evidence Gap You Deserve to Know About

Data on LNG-IUD use in children under age 12 are sparse. A 2019 systematic review in Fertility and Sterility found that most adolescent IUD studies enrolled patients 14 years and older, leaving the sub-12 population represented almost entirely by case reports and small series. Clinicians and families making decisions in this age group are working from extrapolated adult and older-adolescent data, not randomized controlled trial evidence. That is not a reason to avoid the device when the indication is strong; it is a reason to follow these patients more closely and document outcomes carefully.

What Puberty Changes About Your IUD

Puberty rewrites the uterine environment. If your daughter or patient had an IUD placed before age 12, reaching puberty, specifically Tanner stage 3 and beyond, triggers changes that affect IUD function, fit, and planning.

Uterine Growth and Frame Position

The prepubertal uterus averages 3 to 4 cm in length. By mid-puberty, it reaches 6 to 8 cm. This growth is rapid and can shift a previously well-positioned device. A malpositioned IUD is associated with reduced contraceptive efficacy (relevant as the patient begins to become sexually active) and with increased cramping. ACOG Committee Opinion 735 recommends ultrasound confirmation of IUD position in adolescents who develop new pelvic pain or irregular bleeding.

Menstrual Pattern Shifts

Before puberty, the IUD's primary job was endometrial suppression or bleeding management. Once cycles establish, the LNG-IUS will typically cause oligomenorrhea or amenorrhea in 20 to 50 percent of adolescent users by 12 months, per data from the CHOICE Project, with irregular spotting common in the first three to six months of cycling. Families and patients should be counseled to expect this pattern shift and to distinguish it from pregnancy.

Hormonal Axis Considerations

Serum LNG levels from the IUD do not suppress ovulation reliably in all users; in adolescents, ovulation occurs in up to 85 percent of cycles even with a 52 mg LNG-IUS in place. This means once a patient is sexually active, the IUD's contraceptive effect depends primarily on its local mechanisms, not on anovulation. It also means the HPG axis continues to mature normally. Bone density accrual, which peaks in the mid-teens and depends on adequate estrogen, is not significantly impaired by the IUD's low systemic LNG.

Device Lifespan: When Does the IUD Need to Come Out or Be Replaced?

FDA-approved labeling gives Mirena a lifespan of up to 8 years for contraception and up to 5 years for heavy menstrual bleeding. Kyleena is approved for up to 5 years. These durations are validated in adults.

If a device was placed in a nine-year-old in 2018, by 2023 or 2026 it will have reached or exceeded its approved lifespan. The clinical decisions at that point include:

• Remove without replacement if the original indication has resolved (for example, a bleeding disorder now managed with a different hematologic therapy, or an oncologic course completed).
• Replace with a new device if the indication persists, particularly for endometriosis suppression or ongoing heavy menstrual bleeding.
• Switch to an alternative such as a progestin-only pill, implant (etonogestrel, Nexplanon), or continuous combined hormonal contraceptive, depending on the patient's reproductive goals and contraceptive needs as she matures.

The replacement conversation is a natural point to transfer care to adult gynecology if it has not happened already.

Pregnancy, Lactation, and Contraception: Required Information

This section applies once the patient is a sexually active adolescent or adult. The hormonal IUD is one of the most effective reversible contraceptive methods available, with a failure rate of less than 0.1 to 0.8 percent per year depending on the device. However, several critical safety points apply.

If Pregnancy Occurs with an IUD In Place

Pregnancy with an IUD in situ carries serious risks. The risk of ectopic pregnancy is not eliminated by the IUD; if pregnancy does occur, approximately 50 percent of LNG-IUD failures result in ectopic implantation. Any patient with a positive pregnancy test and an IUD in place requires urgent evaluation. The device should be removed as early as possible if the string is visible, because leaving it in place increases the risk of miscarriage, preterm labor, and intrauterine infection.

Levonorgestrel IUD and Pregnancy Safety Classification

The LNG-IUD is contraindicated during established intrauterine pregnancy. Human data on inadvertent intrauterine LNG exposure in early pregnancy are limited to case reports and post-marketing surveillance. The FDA prescribing information does not assign a traditional letter pregnancy category under the current labeling system, but the device is listed as contraindicated in known or suspected pregnancy due to risks of septic abortion, preterm delivery, and fetal harm.

Levonorgestrel and Breastfeeding

If a patient using a LNG-IUD becomes pregnant, delivers, and wishes to breastfeed, the device would be removed during the pregnancy course. A new LNG-IUD can be placed postpartum. Levonorgestrel does transfer into breast milk in small amounts; the infant dose is estimated at 0.1 percent of the weight-adjusted maternal dose, which is considered clinically insignificant. The CDC Medical Eligibility Criteria for Contraceptive Use assigns a Category 2 (benefits generally outweigh risks) for LNG-IUD use from 4 weeks postpartum in breastfeeding women.

Contraception Counseling at Transition

Once the patient is or may become sexually active, the IUD's contraceptive function becomes relevant. CDC U.S. Medical Eligibility Criteria (USMEC) classifies LNG-IUD use in nulliparous adolescents as Category 2, meaning the advantages outweigh theoretical risks. No additional contraceptive method is needed when the IUD is properly positioned and within its approved lifespan.

Female-Specific Conditions the IUD May Affect at Transition

Endometriosis and Pelvic Pain

If the IUD was placed for endometriosis, the transition to adult care should include a reassessment of disease burden. A randomized trial by Vercellini et al. Published in Human Reproduction found that LNG-IUS reduced endometriosis-associated dysmenorrhea scores by 60 percent compared to expectant management at 12 months. Whether this level of suppression persists into adulthood or requires additional surgery or medical therapy should be part of the adult gynecology intake evaluation.

PCOS and Ovulatory Dysfunction

Girls diagnosed with PCOS before age 12, though uncommon, may benefit from continued IUD use for endometrial protection against the effects of chronic anovulation. ACOG Practice Bulletin 194 on PCOS notes that endometrial hyperplasia risk rises with prolonged unopposed estrogen exposure; local progestin delivery from an LNG-IUD is an accepted strategy. The adult gynecologist should document whether continued endometrial protection is still needed or whether cycle regulation with combined hormonal methods is now preferred.

Bleeding Disorders

If the original indication was a bleeding disorder such as Von Willebrand disease or immune thrombocytopenic purpura, the hematology team should be kept in the loop during any IUD removal or replacement. Removal itself can trigger bleeding in patients with severe coagulopathy, and timing the procedure to coincide with factor replacement or DDAVP is standard practice in hematology-gynecology co-management.

Bone Health

Estrogen drives bone mineral density accrual during adolescence, with peak bone mass achieved by the early to mid-twenties. The LNG-IUD does not suppress estrogen production significantly, unlike depot medroxyprogesterone acetate (Depo-Provera), which causes measurable bone density reduction at 12 months of use in adolescents. This is one reason some pediatric gynecologists prefer the IUD over injectable progestin in young patients. The transition visit is a good moment to confirm that the patient's calcium and vitamin D intake meets age-appropriate targets.

Who This Device Is Right For at Transition, and Who Should Reconsider

Candidates to Continue LNG-IUD Through Transition

You may be a good candidate to continue with or replace your LNG-IUD at the transition to adult care if you:

• Have a persistent bleeding disorder and your hematologist confirms ongoing need for endometrial suppression.
• Have confirmed endometriosis and have achieved good pain control with the IUD.
• Want highly effective contraception with minimal systemic hormonal exposure.
• Have migraines with aura, which contraindicate estrogen-containing methods per ACOG guidance.
• Have a personal or family history of deep vein thrombosis that makes estrogen-containing methods higher risk.

Patients Who Should Reassess

A different approach may fit better if you:

• Have completed cancer treatment and no longer need endometrial suppression.
• Have a resolved bleeding disorder or one now controlled by other hematologic means.
• Want to try to conceive in the near future (fertility returns rapidly, typically within one to three months of removal).
• Have developed unexplained abnormal uterine bleeding that warrants evaluation before committing to another IUD cycle.
• Are experiencing IUD-related mood changes or acne that significantly affect quality of life.

Planning the Transition to Adult Gynecologic Care

ACOG Committee Opinion 811 defines the transition from pediatric to adult gynecology as a process, not a single appointment. The transition should ideally begin at age 14 to 16 with progressive steps toward independent adult care by age 18 to 21.

What the Transition Appointment Should Cover

The first dedicated adult gynecology visit for a patient who had a childhood IUD placement should address the following points in this order:

1. Device history and documentation. When was the IUD placed? Which device (Mirena or Kyleena)? What was the original indication? Is the placement record available? Pediatric providers should transfer these records proactively, not wait for a release-of-information request.

2. Current position confirmation. A pelvic ultrasound to confirm intracavitary placement is reasonable if strings are not visible at speculum exam, or if the patient reports new pelvic pain. ACOG Committee Opinion 735 supports ultrasound verification in adolescents.

3. Lifespan calculation. Calculate whether the device is within or beyond its approved lifespan. A Mirena placed in 2017 in an eight-year-old is now beyond its 8-year labeling as of 2025.

4. Indication reassessment. Is the original reason for placement still present and still requiring an IUD specifically?

5. Contraceptive counseling. If the patient is sexually active or anticipates becoming sexually active, explicit counseling about the IUD's contraceptive function, its limits (not protective against STIs), and additional barrier method use is mandatory.

6. Cervical cancer screening plan. ACOG and USPSTF guidelines recommend starting Pap smear screening at age 21, regardless of sexual debut. The IUD does not change this schedule.

Practical Steps for Families and Patients

Getting ready for this transition is simpler if you approach it with a checklist.

• Ask the pediatric gynecologist for a written summary of the placement: date, device brand, lot number, indication, and any complications.
• Bring this document to the first adult gynecology visit.
• Know the device expiration date and put a reminder on your calendar 6 months before that date.
• Ask your new adult provider at the first visit whether strings are visible and whether an ultrasound is needed.
• Discuss STI prevention separately from the IUD; the device offers no protection against chlamydia, gonorrhea, or other sexually transmitted infections.

"The transition from pediatric to adult gynecology is one of the most underleveraged moments in a young woman's reproductive health timeline," says Rachel Goldberg, MD, WomanRx editorial board member and board-certified OB-GYN. "For girls who had IUDs placed in childhood for medical reasons, that first adult visit is not just a formality. It is the moment to audit everything: the device, the indication, the contraceptive counseling, and the patient's own understanding of her own body."

Removing or Replacing the IUD: What to Expect

Removal in an Adolescent or Young Adult

In most patients with visible strings, IUD removal takes under one minute in clinic with no anesthesia. Adolescents who underwent their original placement under anesthesia (common in the pediatric setting) sometimes expect removal to be equally involved. It is usually much simpler once the uterus has matured and the cervix has softened.

Cramping during and after removal is common, lasting minutes to hours. Over-the-counter ibuprofen 600 to 800 mg taken one hour before the appointment reduces procedural discomfort, per a 2018 Cochrane review on IUD insertion pain.

If strings are not visible (possible if they were cut short at the time of placement, or if the device has partially migrated), removal requires ultrasound guidance and may need to be done in an operating room setting. This is more likely in patients whose device was placed before age 10.

Fertility After Removal

Ovulatory cycles and fertility return quickly after LNG-IUD removal. A prospective study published in Human Reproduction found that 71 percent of former LNG-IUD users who wanted to conceive did so within 12 months of removal, comparable to women who stopped barrier contraception. If the original indication was endometriosis, fertility may be more nuanced and should be addressed with a reproductive endocrinologist.

Pregnancy and Lactation: Complete Safety Summary

Pregnancy: The LNG-IUD is contraindicated during confirmed intrauterine pregnancy. If a pregnancy occurs with the device in situ, ectopic pregnancy must be excluded immediately. Removal is recommended as soon as possible if the strings are accessible. FDA labeling states that the device should not be used during pregnancy and that insertion during a pregnancy may cause fetal harm or pregnancy loss.

Lactation: Small amounts of levonorgestrel transfer into breast milk. The NIH LactMed database characterizes infant exposure as negligible and does not recommend avoiding LNG-IUD use in breastfeeding mothers. Placement from 4 weeks postpartum is acceptable per CDC guidance.

Contraception requirements: The IUD is itself the contraceptive. No additional hormonal method is needed. STI prevention requires a barrier method, as the IUD does not reduce transmission risk.